Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single-Arm Meta-Analysis - PubMed
3 hours ago
- #Acute Myeloid Leukemia
- #Meta-Analysis
- #Venetoclax
- Venetoclax combined with intensive chemotherapy shows antileukemic activity in relapsed/refractory AML.
- Pooled complete remission rate was 27.0%, composite complete remission 51.45%, and overall response rate 63.79%.
- Common adverse events included febrile neutropenia (71.38%) and pneumonia (23.6%).
- The analysis supports further prospective trials to compare this combination with standard salvage therapies.